Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Diseaseswe target
    • Diseases we target
    • Leber Hereditary Optic Neuropathy (LHON)
    • Retinitis Pigmentosa (RP)
    • Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
    • Clinical development Summary
  • Investors
    • Company Overview
    • Financial press releases
    • Events & presentations
    • Stock information & Financial agenda
    • Governance
    • Documentation
  • Media

Technologies we are applying

We are at the cutting edge of ophthalmology, gene therapy and drug development in our search for solutions for patients with neurodegenerative diseases. Our products combine a gene therapy-based approach with our core proprietary technology platforms of mitochondrial targeting sequence, or MTS, and optogenetics.
  • Home >
  • Our technologies >
  • Technologies we are applying

Our technologies

  • Gene Therapy
  • Mitochondrial Targeting Sequence (MTS)
  • Optogenetics
© 2023 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page